Brief by Shorts91 Newsdesk / 12:18pm on 06 Jan 2024,Saturday India
In response to 141 child deaths linked to Indian cough syrups in Gambia, Uzbekistan, and Cameroon, the Indian government enforces stricter pharmaceutical manufacturing standards. The $50 billion industry faces heightened scrutiny, with companies required to ensure drug quality, safety, and efficacy. A government notification mandates satisfactory test results before marketing products, addressing concerns about raw material testing. Large manufacturers have six months, while smaller ones get a 12-month deadline, causing some to seek extensions due to heavy debts. The move aims to restore confidence in India's pharmaceutical sector after recent international controversies.
